

# Evidence-Based Research and Clinical Application of Adverse Reactions and Management Strategies for Cancer Treatment Drugs

**Ahmad Raddah Almasoudi<sup>1</sup>, Badr Mohammed Bayazeed<sup>2</sup>, Razan Hassan Ali Alhazmi<sup>3</sup>, Suha Ezzat Sharaf<sup>4</sup>, Maram Battah Alshammari<sup>5</sup>, Naif Talal Alzaid<sup>6</sup>, Abdulaziz Salman Aloqayfi<sup>7</sup>, Asmaa kamel Almatrafi<sup>8</sup>, Ali Mohammad Safar Alzahrani<sup>9</sup>, Saad Suliman Ajaj Alenazi<sup>10</sup>.**

1. Pharmacist at King Faisal Hospital in Makkah
2. Pharmacist at King Faisal Hospital in Makkah
3. Pharmacist at Alyamama Hospital in Riyadh
4. Pharmacist at King Faisal Hospital in Makkah
5. Pharmacist at King Faisal Hospital in Makkah
6. Pharmacist Technician at King Faisal Hospital in Makkah
7. Pharmacist Technician at King Faisal Hospital in Makkah
8. Pharmacist Technician at Maternity and children's Hospital in Makkah
9. Pharmacist Technician at Kudai and Alhijra Primary Healthcare Center in Makkah
10. pharmacist at Primary Healthcare Gilaneh in Riyadh

## Abstract

Although chemotherapy-associated adverse events are important in oncology practice and there are many different interventions to reduce them, there have been few systematic attempts to identify, critically evaluate, and compile all of the evidence regarding the effectiveness of these interventions. Survivors may encounter adverse effects during and after therapy, or they may manifest throughout the months and years following treatment. The most popular pharmaceutical and non-pharmacological therapeutic approaches, Guidelines for evidence-based clinical practice for their proper management, and the molecular mechanisms underlying each of these side effects are all discussed and critically assessed by researchers. Researchers also go over risk variables and validated risk-assessment tools for determining which individuals are most likely to suffer side effects from chemotherapy and which ones can benefit from successful therapies. Lastly, experts point to promising new supportive care options for the growing number of cancer survivors who are still at risk for negative side effects after their treatments.

**Keywords:** Adverse Reactions, Management Strategies, Cancer Treatment Drugs

## Introduction

Whether used alone or in combination with systemic targeted immunotherapeutic medications and/or radiation therapy, systemic therapy with cytotoxic drugs—referred to as chemotherapy in this Review—remains a mainstay of cancer treatment for the majority of human cancers. Chemotherapy patients are susceptible to a number of side effects that have a significant impact on their morbidity, mortality, and treatment expenses. In addition to directly affecting a patient's symptoms and health-related quality of life (HR-QOL), treatment-associated adverse events may also make it more difficult to administer additional treatment to stop the disease from returning (Kuderer et al., 2022).

A variety of emotional side effects, including anxiety, despair, and fear of cancer recurrence (FCR), are additional long-term consequences of chemotherapy and other cancer treatments. Both treatment-related and patient-related factors influence the frequency of these negative effects, which differs with toxicities. Additionally, the growing financial burden (also known as "financial toxicity") related to anticancer treatment is still a significant worry, despite the fact that it is frequently ignored. Even though chemotherapy is frequently linked to the long-term and late side effects covered here, other anticancer treatments such as endocrine therapy, targeted medicines, and immunotherapies can also cause them (Kuderer et al., 2022).

## Literature review

### 1. Adverse Reactions

Symptoms and indicators differ for each patient. Minutes to hours after drug exposure, typical symptoms include mucocutaneous signs (flushing, urticaria, itching) in up to 90% of patients, respiratory symptoms (wheezing) in 40%, circulatory symptoms (hypotension) in 30%–35%, and stomach symptoms (nausea, vomiting, cramps,

diarrhea). A reaction is more likely to be severe the faster it develops. With "influenza-like" symptoms (fever, chills, muscle soreness, rash, exhaustion, headache, etc.), the majority of reactions are mild to severe and manifest during the first few hours, usually with the initial infusion. Acute laryngopharyngeal dysesthesia, a cold-related feeling of dyspnea, trouble swallowing or speaking, jaw stiffness, and strange tongue and/or pharyngeal sensations during or after oxaliplatin infusion are typical adverse effects of the drug. Within the first 24 hours of taking it, irinotecan-related cholinergic syndrome manifests as diarrhea, emesis, diaphoresis, cramping in the abdomen, and, less frequently, hyperlacrimation and rhinorrhea (Conroy & Naidoo, 2022).

## 2.1 Cancer-related fatigue

One of the most difficult and persistent side effects of cancer and cancer treatment is fatigue. Patients with cancer frequently report feeling physically, emotionally, and/or cognitively exhausted all the time. After repeated exposure to anticancer treatments, CRF typically develops throughout therapy with a higher cumulative intensity. After therapy ends, these symptoms frequently become better in a matter of months (Vaz-Luis et al., 2022).




Figure 1. The most frequent complaint from cancer patients undergoing chemotherapy is fatigue, which has several risk factors (Inglis et al., 2019).

One of the most difficult and persistent side effects of cancer and cancer treatment is fatigue. Patients with cancer frequently report feeling physically, emotionally, and/or cognitively exhausted all the time. After repeated exposure to anticancer treatments, CRF typically develops throughout therapy with a higher cumulative intensity. After therapy ends, these symptoms frequently become better in a matter of months (Inglis et al., 2019).

## 2.2 Management and guideline recommendations

Due to the paucity of nutrition research specifically pertaining to CRF, more studies that employed nutritional therapies to alleviate tiredness and inflammation were reviewed. Fatigue levels seem to be influenced by dietary intake before, during, and after cancer therapy. Lean mass and body composition may be preserved with increased protein consumption. Dietary patterns that reduce inflammation, like the Mediterranean diet and other plant-based diets, appear to be tolerated by cancer survivors and may also reduce fatigue. The energy levels of cancer survivors may be increased by taking probiotics, ginseng, or ginger supplements. Cancer survivors' fatigue may be treated with nutritional therapies, either by itself or in conjunction with other interventions (Inglis et al., 2019).

While exercise with psychological therapies would be most helpful when treatment is finished, exercise appears to be the most effective intervention for individuals with acute or delayed cancer-related fatigue receiving primary treatment. Although their regular implementation is still difficult, there is growing evidence that multidisciplinary exercise-based programs can enhance patient outcomes. To produce data about the possible use of integrative and complementary therapies (such as touch therapy, stress reduction, and acupuncture) in the treatment of fatigue, more study is required (David et al., 2021).

## 3.1 Chemotherapy-induced peripheral neuropathy

Peripheral neuropathy is a prevalent condition that typically manifests as pain, tingling, numbness, and heightened temperature sensitivity, among other symptoms. Other comorbidities, such as diabetes, a family history of neuropathy, or pre-existing neuropathy, are taken into account when assessing risk for CIPN. Treatment with certain chemotherapeutic drugs, including as vinca alkaloids (like vincristine) and platinum-based treatments (such as cisplatin, carboplatin, and oxaliplatin), is often linked to CIPN. The replacement of these medicines with less neurotoxic medications should be taken into consideration as part of a collaborative decision-making process between patients and physicians in patients who are at high risk of treatment-related problems. The goal of continuing research on CIPN risk factors is to improve risk calculation in a way that benefits both patients and doctors by identifying genetic predictors and blood-based biomarkers (Chan et al., 2019).




Figure 2. Although patients with severe cancer-induced peripheral neuropathy may also experience autonomic and motor symptoms, the most prevalent manifestations of cancer-induced peripheral neuropathy are pain and either positive or negative sensory symptoms.

### **3.2 Management and guideline recommendations**

In order to lower the risk of chronic persistent CIPN after treatment is over, which could result in more permanent chronic injury, clinicians should talk about dose reductions, delays, or a change in treatment regimen with patients who have CIPN symptoms throughout therapy as a component of a collaborative decision-making process. The possible advantages of cancer treatment should be weighed against the possibility of long-term harm and functional impairments while making decisions. The only medication proven to help patients with chronic painful CIPN in an RCT is duloxetine (Loprinzi et al., 2020).

Additionally, this medication is linked to high expenses and additional side effects in certain patients, including xerostomia, nausea, and constipation. Supplements are not yet sufficiently well-established to be recommended for the treatment of peripheral neuropathy. Multivitamin use may be a stand-in for other related behaviors that are the real drivers of CIPN decrease, even if it has been linked in retrospective studies to better CIPN results. Furthermore, supplements (such as multivitamins) can raise the cost burden on patients and have a negative impact on CIPN and cancer outcomes (Loprinzi et al., 2020).

### **4.1 Chemotherapy-related cognitive impairment**

The type of cancer, anticancer treatments administered, and comorbidities are risk factors for cognitive impairment, a complex illness. It is true that comorbidities unrelated to cancer, like those brought on by aging, can also impair cognitive performance and reduce its recovery following treatment. Research suggests that hunger and micronutrients affect cognitive function. Additionally, observational clinical studies have linked anemia to cognitive impairment; nevertheless, erythropoietin is not currently advised as a therapy (Duijts et al., 2016).

### **4.2 Management**

Current suggested management options for cognitive impairment include patient education, cognitive training, rehabilitation, exercise, and mind-body therapy, tailored to each patient's unique symptom burden and concomitant comorbidities and pharmaceutical therapies. Before pharmacological medicines like memantine, donepezil, and modafinil can be taken on a regular basis, more research is required to confirm their usefulness in this situation. Physical therapists are qualified to evaluate and recommend a suitable exercise regimen in light of any potential mobility or physical restrictions brought on by cancer treatment, which may change as the disease is being treated (Campbell et al., 2019).

### **5.1 Cardiotoxicity**

Heart problems among cancer survivors have dramatically increased due to the cardiotoxicity of various anticancer treatments and a number of risk factors shared by cancer and heart disease, especially in an aging population. These problems include long-term cardiovascular issues like cardiomyopathies and acute life-threatening toxicities including myocarditis, arrhythmias, and coronary vasospasms. As a result, cancer survivors are at a higher risk of cardiovascular events. As a result, the specialty of cardio-oncology has developed to specifically address this elevated risk of cardiovascular problems and the corresponding requirement for multimodal care (Desai et al., 2019).

### **5.2 Management and guideline recommendations**

The European Society of Cardiology places a high priority on cardiovascular monitoring, which includes strain imaging echocardiography screening for cancer patients undergoing treatment who are at high risk of cardiac problems. Additionally, it is necessary to address health-promotion tactics like exercise and a balanced diet. Cardiologists should treat patients who report toxicity as soon as possible, and interdisciplinary management with oncology specialists is recommended. In asymptomatic patients receiving cardiotoxic therapies, the precise function and timing of blood-based cardiac monitoring, such as natriuretic peptide B and high-sensitivity troponin tests, are yet unknown. Practical and focused individualized prevention and treatment treatments should be made possible by improved risk stratification to identify individuals who most require cardioprotective measures, more advanced cardiac imaging, and the use of proven cardiac toxicity risk tools and biomarkers (Curigliano et al., 2020).

### **6.1 Pulmonary toxicity**

Chemotherapy-induced pulmonary toxicity (CIPT) may be caused by direct side effects or secondary infectious lung issues as a result of immunosuppression associated with the medication. This study focuses on the direct pulmonary toxicity of chemotherapy, which can result in both immediate and long-term lung damage in cancer survivors. The risk of pulmonary toxicity in patients receiving anticancer therapy depends on the particular medications used, their dosages, and whether or not they already have a lung condition. Baseline pulmonary function tests can be used to identify patients who are at high risk of such toxicity, especially those who are prescribed known causative medications including gemcitabine, busulfan, bleomycin, and methotrexate. Bleomycin causes four types of lung

damage: persistent progressive pulmonary fibrosis, cryptogenic organizing pneumonia, hypersensitivity pneumonitis, and acute chest pain syndrome during infusion(Dhamija et al., 2020).

## 6.2 Management

To determine baseline lung function and inform judgments about the administration of medications known to cause CIPT, pretreatment pulmonary function tests are conducted. Routine screening for lung injury, especially in individuals on non-bleomycin medications, is not typical practice. The FDA label for bleomycin states that in order to detect toxicities, lung diffusing ability for carbon monoxide should be assessed at baseline and then every month after that. If the lung's carbon monoxide diffusing capacity falls below 30–35% of its pretreatment value, therapy should be discontinued(Freites-Martinez et al., 2020).

Possessing an elevated suspicion of pulmonary toxicity, particularly in patients at high risk of such consequences, and assessing and monitoring pulmonary symptoms throughout anticancer treatment are crucial aspects of management to promptly identify significant toxicities. Important components in the treatment of pulmonary toxicity include glucocorticoid therapy, drug withdrawal, and supportive care(Freites-Martinez et al., 2020).

### 7.1 Anxiety, distress, depression and fear of recurrence

Patients with cancer of all stages, including those receiving chemotherapy, often experience emotional suffering; the most common psychiatric diagnoses are anxiety and depression. Cognitive dysfunction, severe comorbid illness, a history of mental illness or substance abuse, depression, or suicide attempts, trauma and/or abuse (physical, emotional, sexual, and/or verbal), social issues (immigration status, financial hardships, family conflicts, social isolation, and current substance use), younger age (less than 65 years), and uncontrolled symptoms are some of the risk factors for distress that have been identified. Socioeconomic deprivation and single status have also been identified in studies as potential risk factors(Bergerot & Pal, 2022).

### 7.2 Management

Targeted psychosocial interventions that have demonstrated efficacy in treating emotional symptoms include psychotherapy, cognitive-behavioral approaches (including cognitive-behavioral therapy, cognitive-existential therapy, problem-solving therapy, and systematic desensitization), mind-body modalities (including mindfulness-based therapy, physical exercise, hypnosis, and relaxation with guided imagery), supportive therapy (including supportive-expressive therapy and supportive counseling), and complementary and alternative medicine(Bergerot & Pal, 2022).

There are now a number of interventions based on these instruments that have shown effective in treating both physical and emotional issues. Additionally, these programs can be used to support patients and caregiver groups, encourage good communication between patients and their medical care team, advance health literacy, offer psychosocial education and information, track patient-reported outcomes, and assist patients in managing their physical and emotional symptoms on their own(Bergerot & Pal, 2022).

## Conclusion

In order to guarantee that cancer survivors are receiving the best treatment possible, primary care physicians play a crucial role in care coordination, which is a crucial aspect of survivorship care. Care coordination is crucial, especially for survivors who have several medical comorbidities brought on by aging, chronic illnesses, and side effects from cancer therapy. Numerous implementation science programs focus on lifestyle modifications (such as quitting smoking, controlling one's diet, and exercising) that are necessary to enhance health outcomes. Frequent exercise can help with physical function, depressive symptoms, HR-QOL, CRF, and other outcomes related to a cancer diagnosis and treatment. A thorough framework for health promotion is needed, starting with diagnosis and continuing through acute treatment, survivorship, and end-of-life care. Importantly, cancer patients' results are influenced by the socioeconomic environment, sometimes referred to as the social determinants of health. Health outcomes across different populations can be disproportionately impacted by social determinants of health, including access to and quality of health care, education, economic security, and community environment.

## References

1. Chan, A., Hertz, D. L., Morales, M., Adams, E. J., Gordon, S., Tan, C. J., Staff, N. P., Kamath, J., Oh, J., Shinde, S., Pon, D., Dixit, N., D'Olimpio, J., Dumitrescu, C., Gobbo, M., Kober, K., Mayo, S., Pang, L., Subbiah, I., . . . Lustberg, M. B. (2019). Biological predictors of chemotherapy-induced peripheral neuropathy (CIPN): MASCC neurological complications working group overview. *Supportive Care in Cancer*, 27(10), 3729–3737. <https://doi.org/10.1007/s00520-019-04987-8>

2. Conroy, M., & Naidoo, J. (2022). Immune-related adverse events and the balancing act of immunotherapy. *Nature Communications*, 13(1). <https://doi.org/10.1038/s41467-022-27960-2>
3. Curigliano, G., Lenihan, D., Fradley, M., Ganatra, S., Barac, A., Blaes, A., Herrmann, J., Porter, C., Lyon, A., Lancellotti, P., Patel, A., DeCara, J., Mitchell, J., Harrison, E., Moslehi, J., Witteles, R., Calabro, M., Orecchia, R., De Azambuja, E., . . . Jordan, K. (2020). Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. *Annals of Oncology*, 31(2), 171–190. <https://doi.org/10.1016/j.annonc.2019.10.023>
4. David, A., Hausner, D., & Frenkel, M. (2021). Cancer-Related Fatigue—Is there a role for complementary and integrative medicine? *Current Oncology Reports*, 23(12). <https://doi.org/10.1007/s11912-021-01135-6>
5. Desai, A., Noor, A., Joshi, S., & Kim, A. S. (2019). Takotsubo cardiomyopathy in cancer patients. *Cardio-Oncology*, 5(1). <https://doi.org/10.1186/s40959-019-0042-9>
6. Dhamija, E., Meena, P., Ramalingam, V., Sahoo, R., Rastogi, S., & Thulkar, S. (2020). Chemotherapy-induced pulmonary complications in cancer: Significance of clinicoradiological correlation. *Indian Journal of Radiology and Imaging - New Series/Indian Journal of Radiology and Imaging/Indian Journal of Radiology & Imaging*, 30(01), 20–26. [https://doi.org/10.4103/ijri.ijri\\_178\\_19](https://doi.org/10.4103/ijri.ijri_178_19)
7. Duijts, S. F., Van Der Beek, A. J., Boelhouwer, I. G., & Schagen, S. B. (2016). Cancer-related cognitive impairment and patients' ability to work: a current perspective. *Current Opinion in Supportive and Palliative Care*, 11(1), 19–23. <https://doi.org/10.1097/spc.0000000000000248>
8. Freites-Martinez, A., Santana, N., Arias-Santiago, S., & Viera, A. (2020). CTCAE versión 5.0. Evaluación de la gravedad de los eventos adversos dermatológicos de las terapias antineoplásicas. *Actas Dermo-Sifiliográficas*, 112(1), 90–92. <https://doi.org/10.1016/j.ad.2019.05.009>
9. Inglis, J. E., Lin, P., Kerns, S. L., Kleckner, I. R., Kleckner, A. S., Castillo, D. A., Mustian, K. M., & Peppone, L. J. (2019). Nutritional Interventions for Treating Cancer-Related Fatigue: A Qualitative Review. *Nutrition and Cancer*, 71(1), 21–40. <https://doi.org/10.1080/01635581.2018.1513046>
10. Kuderer, N. M., Desai, A., Lustberg, M. B., & Lyman, G. H. (2022). Mitigating acute chemotherapy-associated adverse events in patients with cancer. *Nature Reviews Clinical Oncology*, 19(11), 681–697. <https://doi.org/10.1038/s41571-022-00685-3>
11. Loprinzi, C. L., Lacchetti, C., Bleeker, J., Cavaletti, G., Chauhan, C., Hertz, D. L., Kelley, M. R., Lavino, A., Lustberg, M. B., Paice, J. A., Schneider, B. P., Smith, E. M. L., Smith, M. L., Smith, T. J., Wagner-Johnston, N., & Hershman, D. L. (2020). Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline update. *Journal of Clinical Oncology*, 38(28), 3325–3348. <https://doi.org/10.1200/jco.20.01399>
12. Vaz-Luis, I., Di Meglio, A., Havas, J., El-Mouhebb, M., Lapidari, P., Presti, D., Soldato, D., Pistilli, B., Dumas, A., Menvielle, G., Charles, C., Everhard, S., Martin, A., Cottu, P. H., Lerebours, F., Coutant, C., Dauchy, S., Delaloge, S., Lin, N. U., . . . Michiels, S. (2022). Long-Term Longitudinal Patterns of Patient-Reported Fatigue After Breast Cancer: A Group-Based Trajectory Analysis. *Journal of Clinical Oncology*, 40(19), 2148–2162. <https://doi.org/10.1200/jco.21.01958>